drugset / Trial / NCT02078843

Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors

NCT02078843 ↗

NaSingle-groupOpen-labelDiagnostic

Summary

The investigators hypothesize that the new imaging method Gallium-68-DOTATATE has a higher diagnostic value in the detection of neuroendocrine tumors than the established imaging method Indium-111-Octreoscan. Therefore, the investigators will perform both imaging procedures in patients with suspected or confirmed neuroendocrine tumors. Subsequently, the investigators will compare the diagnostic performance of both methods.

Timeline

Start
2014-03
Primary completion
2016-08
Completion
2016-08

Outcome

Outcome not reported

Stopped: “Superiority of one imaging method”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject 68Ga-DOTATATE Diagnostic / imaging agent — —
Subject Indium-111-Octreoscan (standard test) Unknown — —